An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

Uffe Klausen, Nicolai Gronne Dahlager Jorgensen, Jacob Handlos Grauslund, Shamaila Munir Ahmad, Anne Ortved Gang, Evelina Martinenaite, Stine Emilie Weis-Banke, Marie Fredslund Breinholt, Guy Wayne Novotny, Julie Westerlin Kjeldsen, Morten Orebo Holmstrom, Lone Bredo Pedersen, Christian Bjorn Poulsen, Per Boye Hansen, Ozcan Met, Inge Marie Svane, Carsten Utoft Niemann, Lars Moller Pedersen, Mads Hald Andersen*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Original languageEnglish
JournalOncoImmunology
Volume10
Issue number1
DOIs
Publication statusPublished - 1 Jan 2021

Keywords

  • PD-l1
  • PD-l2
  • immune modulatory vaccine
  • anti-regulatory T cells
  • anti-tregs
  • follicular lymphoma

Cite this